{"nctId":"NCT01185782","briefTitle":"SJ-0021 (Gonalef®) Versus Purified Pituitary Gonadotropin (Fertinorm-P®) for Ovulation Induction in Japanese Infertile Women","startDateStruct":{"date":"2007-02"},"conditions":["Infertility","Ovulation Induction"],"count":300,"armGroups":[{"label":"SJ-0021 group","type":"EXPERIMENTAL","interventionNames":["Drug: Gonalef® (Follitropin alfa)"]},{"label":"Purified pituitary gonadotropin group","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Purified pituitary gonadotropin (Fertinorm-P®)"]}],"interventions":[{"name":"Gonalef® (Follitropin alfa)","otherNames":["Gonalef®","follitropin alfa","recombinant human follicle-stimulating hormone","r-hFSH","SJ-0021"]},{"name":"Purified pituitary gonadotropin (Fertinorm-P®)","otherNames":["Fertinorm-P®","purified urinary human follicle-stimulatin hormone","urofollitropin","u-hFSH"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Women aged 20 to 39 years (inclusive) who hope to bear children\n* Subjects who failed to achieve ovulation or pregnancy despite 2 cycles or more of anti-estrogen therapies (clomiphene citrate, cyclofenil, etc.)\n* Subjects who exhibited withdrawal bleeding in a progesterone test (Includes spontaneous menstruation in subjects with anovulatory cycles.)\n* Subjects having a body mass index between 17.0 and 28.0 at the time of baseline tests\n* Subjects who voluntarily consented in writing to participate in the clinical trial\n\nExclusion Criteria:\n\n* Subjects with ovarian tumors\n* Subjects with ovarian enlargement not due to PCOS\n* Subjects with genitourinary hemorrhage of unknown cause\n* Subjects who were or may be pregnant, or who were lactating\n* Subjects with history of allergic reaction or hypersensitivity to gonadotropin\n* Subjects with dysfunction of heart, lungs, kidneys, or cardiovascular systems of Grade 2 or higher (in compliance with the Pharmaceutical and Medical Safety Bureau Notification Yakuan No. 80 \\[issued 29 June 1992\\])\n* Subjects with serum progesterone (P4) level ≥ 5 ng/mL in baseline tests\n* Subjects with malignant tumors\n* Subjects with uterine amenorrhea\n* Subjects with elevated levels of serum gonadotropin due to premature ovarian failure (FSH ≥ 20 mIU/mL)\n* Subjects who were infertile due to known adrenal or thyroid dysfunction\n* Subjects who were diagnosed as having hyperprolactinemia\n* Subjects who had been documented or suspected of having intracranial lesions (e.g., pituitary tumors)\n* Infertile subjects involving gynecological factors other than amenorrhea I or anovulatory cycles, and for whom ovulation induction therapy was found to be contraindicated\n* Subjects who had participated in another clinical study within 6 months prior to start of the IMP administration\n* Subjects who had been administered SJ-0021 in the past\n* Subjects whose participation in this clinical trial was otherwise deemed inappropriate by the investigator or sub-investigator","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"20 Years","maximumAge":"39 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Ovulation","description":"Participants were considered to have ovulated if serum progesterone (P4) level was greater than or equal to 5 nanogram (ng)/mL on Day 6±1 or 9±1 during the post-treatment assessment period, or if the participant became clinically pregnant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.1","spread":null},{"groupId":"OG001","value":"82.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Dominant Follicle Achieving 18 mm in Mean Diameter","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"117","spread":null},{"groupId":"OG001","value":"125","spread":null}]}]}]},{"type":"SECONDARY","title":"Time for Dominant Follicle to Achieve 18 mm in Mean Diameter","description":"Dosing time length was calculated as number of days from the first administration of the IMP until the mean diameter of the dominant follicle was confirmed to have reached 18 mm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1","spread":"5.1"},{"groupId":"OG001","value":"12.1","spread":"4.2"}]}]}]},{"type":"SECONDARY","title":"Total Dose of the Investigational Medicinal Product (IMP) Administered to Participants With Dominant Follicle Achieving 18 mm in Mean Diameter","description":"Total dose of IMP administered was defined as the cumulative dose administered from the start of treatment with IMP until the mean diameter of the dominant follicle reached 18 mm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"959.29","spread":"533.32"},{"groupId":"OG001","value":"845.70","spread":"432.88"}]}]}]},{"type":"SECONDARY","title":"Human Chorionic Gonadotropin (hCG) Cancellation Rate","description":"hCG cancellation criterion was defined as the presence of 4 or more ovarian follicles with a mean diameter greater than or equal to 16 mm. If the hCG cancellation criterion was met, the administration of hCG was withheld. Otherwise, a single intramuscular dose of hCG 5000 IU (Japanese Pharmacopoeia- JP) was administered within 24 hours of the last ultrasound examination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":null},{"groupId":"OG001","value":"7.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Single Follicle Maturation Rate","description":"Single follicle maturation was defined as the presence of the dominant follicle with a mean diameter of 18 mm or greater without concurrent presence of other follicles of 14 mm or larger in diameter.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"43.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Biochemical Pregnancy Rate","description":"Biochemical pregnancy was defined as a positive pregnancy test (urinary beta-hCG test) on Day 28-31 of the post-treatment assessment period","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","spread":null},{"groupId":"OG001","value":"15.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Pregnancy Rate","description":"Clinical pregnancy was defined as existence of at least one ultrasonography confirmed gestational sac in the uterus, with or without heartbeat.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1","spread":null},{"groupId":"OG001","value":"14.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Ovulation Rate, Where Ovulation is Defined as a Serum P4 Level Greater Than or Equal to 10 ng/mL or Clinical Pregnancy","description":"For this secondary endpoint, participants were considered to have ovulated if serum P4 level was more than or equal to 10 ng/mL on Day 6±1 or 9±1 during the post-treatment assessment period, or if the participant became clinically pregnant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.3","spread":null},{"groupId":"OG001","value":"75.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and AEs Leading to Study Drug Discontinuation","description":"AEs: Any untoward medical occurrence in the form of signs, clinically significant abnormalities in laboratory findings, diseases, symptoms, or worsening of complications. TEAEs: AEs that occur during treatment with the IMP. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition. Participants who discontinued from the study due to AE were also recorded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With OHSS","description":"OHSS is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":129},"commonTop":["Nasopharyngitis","Abdominal pain lower","Abdominal distension","Headache","Ovarian hyperstimulation syndrome"]}}}